Background: Mice lacking the BCL-6 gene product exhibit overexpression of T helper cell type 2 cytokines, and multi-organ inflammatory responses characterized by eosinophilia and infiltration by IgEϩ B lymphocytes. Elevated IgE levels appear to result from loss of BCL-6's role in repression of the Stat6-dependent processes of I-epsilon transcription and IgE class-switching. Understanding the regulation of the BCL-6 gene expression is therefore relevant to the allergic response, due to the IgEdependent activation of mast cells and basophils.
Introduction
The BCL-6 gene encodes for a transcriptional repressor that contains six Kruppel-like zinc fingers at its carboxyl-terminus (1) (2) (3) , and an N-terminal POZ domain homologous to members of zinc finger transcription factors (4) (5) (6) (7) (8) . Previous studies have shown that BCL-6 mRNA is readily detectable in most mature B-cell lines and many tissues, and at low levels in T-, myeloid, and erythroid cells (9, 10) . Immunohistologic experiments demonstrate that there is strong nuclear expression of BCL-6 protein in follicular lymphomas, diffuse large B-cell lymphomas, Burkitt's lymphomas, and nodular, lymphocyte-predominant Hodgkin's disease, with the highest levels in germinal center B lymphocytes (11, 12) . Transient transfection assays indicate that BCL-6 can function as a potent sequence-specific transcriptional repressor through its consensus DNA binding sequence (13, 14) , which resembles the binding sites for several STAT factors (15) . Chromosomal translocations resulting in promoter substitutions of the BCL-6 gene recurrently occur in the diffuse large cell lymphoma (DLCL), a subtype of non-Hodgkin's lymphomas (16, 17) . These rearrangements include replacements of the 5' regulatory region of the BCL-6 gene with regions of the immunoglobulin gene locus or other translocation partners, while invariably leaving the BCL-6 coding region intact (16) (17) (18) (19) (20) . Besides frequent chromosomal translocations, somatic hypermutation similar to Ig gene is observed in the first intron of the BCL-6 gene (21, 22) . Mice with a disrupted BCL-6 gene do not develop germinal centers and have increased expression of Th2 cytokines (15, 23) . These findings strongly suggest that BCL-6 play critical roles in regulating B-and T-cell responses, and that its deregulated expression may contribute to lymphomagenesis.
Despite a great deal of work focused on this gene since 1993, its precise biological function and transcriptional regulation are poorly understood. In this study, we report the differential expression of BCL-6 in a pair of isogenic human B lymphoblastoid cells, Jijoye and Clone-13, as determined first by mRNA differential display. RT-PCR and Northern blot analysis further verify that BCL-6 mRNA is readily detectable in Clone-13, the mutant cell line, but only barely detected in its parental cell line, Jijoye. Corresponding to the mRNA level, BCL-6 protein is only detected in Clone-13, but not in Jijoye. Nuclear runon assays indicate that BCL-6 gene expression is mainly regulated at the transcriptional level in the two cell lines. Whereas multiple sequence differences are identified in the first introns of the BCL-6 genes within the cell lines, these mutations do not have significant effects on the expression of the downstream reporter gene. Our results indicate that the distinct expression of the BCL-6 gene in Jijoye/Clone-13 is not due to mutations in the first intron or promoter substitutions caused by chromosomal translocations. It is more likely that the differences are due to defects in trans-acting factor(s). This pair of isogenic B-cell lines therefore provides an important system for understanding the regulation of BCL-6 gene expression.
Materials and Methods

Construction of Plasmids
The pGL2-Control Vector (Promega, Madison, WI, USA) with an SV40 promoter and enhancer was used in transfection experiments. The promoterless plasmid pGL2-Basic (Promega) was included as background. A 4.7-kb Kpn I-Bgl II fragment from pLA/B14.5 was ligated into pGL2 Basic to generate plasmid BlucKp/Bg. Plasmids J4, J6, C1, and C2 were generated by PCR. They have the same promoter region as BlucKp/Bg; the first exon and part of the first intron were amplified from different alleles of Jijoye and Clone-13. J4 and J6 contain fragment derived from the two alleles of Jijoye, respectively. C1 and C2 were derived from Clone-13. The sequences of the oligos used in PCR are as follows (position ϩ1 refers to the first nucleotide of the BCL-6 cDNA): ) suspended in 300 l complete media were transferred to the cuvette and mixed well with DNA before pulsed at 310 V, 1000 uF using an Invitrogen Electroporator II (Invitrogen, Carlsbad, CA, USA). Then cells were incubated at 37 ЊC, 5% CO 2 for 40 hr before harvest for luciferase assay. Luciferase activity was determined using a luminometer (Monolight 2010, Analytical Luminescence Laboratory, Mississauga, Ontario, Canada) following the protocol of Luciferase Assay System (Promega). Relative luciferase values were normalized to ␤-gal expression and shown as percentages of the value of pGL2-Control Vector.
mRNA Differential Display Analysis
Differential display experiments were carried out in a GeneAmp PCR System 2400 (Perkin-Elmer, Norwalk, CT, USA), using a RNAimage Kit (GenHunter, Nashville, TN, USA) according to the manufacturer's instruction. Total RNA was extracted from each cell line using RNA STAT-60 Reagent (TEL-TEST, Friendswood, TX, USA) and then treated with RQ1 RNase-Free DNase I (Promega) to eliminate genomic DNA contamination. The first strand cDNA was synthesized by reverse transcription with H-T11G anchored primer in the presence of MMLV reverse transcriptase, then amplified with a 5Ј arbitrary primer H-AP6 (5Ј-AAGCTTGCACCAT-3Ј) in the presence of 32 P-dCTP (3000 Ci/mmol; ICN, Costa Mesa, CA, USA) and Taq DNA Polymerase (Promega). The amplified products were resolved on a 6% polyacrylamide denaturing sequencing gel. After autoradiography, the bands of interest were recovered and reamplified by PCR.
Cloning and Sequence Analysis
The products of reamplification from differential display were cloned into the vector pUC57/T using the T-cloning Kit (MBI, Vilnius, Lithuania). Four to six independent bacterial colonies were randomly picked up and lysed with the method described by Zhang et al. (27) . The lysates were used as templates for PCR amplification in which M13 forward and reverse primers flanking the cloning site of the vector were used to amplify the fragments containing the inserts. The PCR fragments were sequenced using Delta Taq Cycle Sequencing Kit (Amersham, Cleveland, OH, USA) according to the manufacturer's specification.
Western Blot Analysis Cells (3 ϫ 10 6 ) were resuspended in PBS, lysed with 2ϫ SDS-PAGE sample buffer containing 2-mercaptoethanol, boiled for 5 min, and electrophoresed through a 8% SDS-PAGE gel. The proteins were then electrotransferred to PVDF membranes (Bio-Rad, Hercules, CA, USA). The proteins were immunostained with antibody Bcl-6 (N-3) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by alkaline phosphatase conjugated anti-Rabbit IgG antibodies. Western blot analysis was carried out using a Western-Light Chemiluminescent Detection System (Tropix, Bedford, MA, USA), following the manufacturer's specifications. After Western blot analysis the membrane was stained with amido black to evaluate the equivalency of protein loading.
Nuclear Run-on Transcription Assay
Nuclear run-on assays were performed according to the methods described previously with minor modification (28) . Briefly, approximately 1 ϫ 10 7 cells were collected and washed twice with PBS, and incubated with 2 ml lysis buffer (10 mM Tris-Cl, pH7.4, 10 mM NaCl, 3 mM MgCl 2 , 0.5% NP-40) on ice for 5 min. Nuclei were pelleted for 5 min at 500 ϫ g. After washing once with the lysis buffer without NP-40, the pellets were resuspended in 100 l of storage buffer (50 mM Tris-Cl, pH8.3, 40% glycerol, 5 mM MgCl 2 , 0.1 mM EDTA). One hundred microliters of 2 ϫ reaction buffer (10 mM Tris-Cl, pH8.0, 5 mM MgCl 2 , 300 mM KCl, 5 mM DTT, 1 mM each of ATP, GTP, CTP) and 200 Ci ␣-32 P-UTP (Ͼ800 Ci/mmol; ICN) were added to the nuclei suspension along with 5 l RNasin (Promega). The mixture was incubated at 30 ЊC for 30 min. The reaction was terminated by addition of 40 U RQ1 RNase-Free DNAse I (Promega) and further incubated for 10 min. Then Nuclear RNA was isolated with RNA STAT-60 Reagent as described.
Plasmid pHeboMTBCL6 (10) containing the fulllength BCL-6 cDNA, cloning vector pMT2T, and plasmid pSP64-␥-actin (gift from Dr Tom Maniatis, Harvard University) containing the ␥-actin cDNA were linearized with Kpn I, EcoR I, and EcoR I, respectively. After gel purification, 5 g DNA of each sample was denatured in 0.2 N NaOH at 65 ЊC for 1 hr and then neutralized with 10 volumes of 6ϫ SSC. The DNA was spotted onto a Hybond-Nϩ membrane (Amersham) using a slot blot manifold (Bio-Rad) and then UVcrosslinked. The filters were prehybridized for 16 hr at 65 ЊC in prehybridization buffer (10 mM Tris-Cl, pH 7.5, 300 mM NaCl, 10 mM EDTA, 0.5 g/ml salmon sperm DNA, 0.05% sodium pyrophosphate, 2ϫ Denhardt). Hybridizations were performed with equal amounts of labeled nuclear RNA in hybridization buffer (10 mM Tris-Cl, pH 7.5, 300 mM NaCl, 10 mM EDTA, 0.2% SDS) for 44 hr at 65 ЊC. The filters were washed twice with 2ϫ SSC, 0.1% SDS at room temperature for 10 min, then 0.2ϫ SSC, 0.1% SDS for 30 min at 60 ЊC. After incubation with 2ϫ SSC, 10 g/ml RNase A at 37 ЊC for 30 min, the filters were rinsed twice in 2ϫ SSC before autoradiography.
RT-PCR Assay
A pair of primers specific to the human BCL-6 cDNA (spanning base pairs ϩ427 to ϩ645, covering part of exon 3 and exon 4) was synthesized and used in PCR reactions. Total RNAs treated with RQ1 were reverse transcribed with random primers and M-MLV transcriptase (Gibco-BRL, Gaithersburg, MD, USA). Then 1/10 volume of cDNA was used as template for the following PCR amplification. Thirty cycles were run at 94 ЊC for 1 min, 60 ЊC for 2 min, and 72 ЊC for 3 min. Twenty microliters of each PCR product was analyzed on 1.5% agarose gels stained with ethidium bromide. The same cDNAs were used for amplification of GAPDH and HLA-DR␣ to evaluate the integrity and amount of the RNA samples used in RT-PCR. The sequences of oligonucleotide primers for PCR amplification are as follows:
BCL-6 sense: 5Ј-GTTGTCATTGTTGTGAGCCG-3Ј BCL-6 antisense: 5Ј-CATCACAGCCATGATGTTGC-3Ј (219 bp) DR␣ sense: 5Ј-GAGTT CTATCTGAATCCTG-3Ј Dr␣ antisense: 5Ј-GTTCTGCTGCATTGCTTTTGC-3Ј (643 bp) GAPDH sense: 5Ј-TGATGACATCAAGAAGGTGGT-3Ј GAPDH antisense: 5Ј-CAGTGAGGGTCTCTCTCTTCC-3Ј (301 bp)
DNA and RNA Analysis
Northern Blot Analysis Total RNA samples (20 g per lane) were size fractionated on a 1% formaldehyde agarose gel and transferred to a Hybond-Nϩ membrane (Amersham). A 2.0-kb EcoR I fragment derived from the eukaryotic expression vector pMT2T-BCL-6 (10) was used as probe, 32 P-labeled with MegaPrime DNA Labeling Kit (Amersham) followed by purification with NucTrap Push Columns (Stratagene, La Jolla, CA, USA). Northern blot analysis was performed at 68 ЊC using QuikHyb Hybridization Solution (Stratagene) following the manufacturer's protocol.
Southern Blot Analysis Preparation of high-molecular-weight DNA, restriction enzyme digestion and electrophoresis were performed according to standard procedures. Fifteen micrograms of genomic DNA from Jijoye and Clone-13 were digested by Hind III (New England BioLabs, Beverly, MA, USA), fractionated by 0.9% agarose gel electrophoresis, denatured, and transferred to a Hybond-Nϩ membrane (Amersham). Probe 1, a 2.9-kb Avr II-Xho I fragment derived from plasmid pLA/B14.5, covers the ϳ3-kb 5'-flanking region. Probe 2, a 4.2-kb fragment digested from pLA/B14.5 by Bgl II, spans through the hot-spot region for chromosomal translocations of the BCL-6 gene. Hybridization was performed under the same condition as Northern blot, except that the temperature was reduced to 65 ЊC for hybridization and washing.
Results
The BCL-6 Gene is Differentially Expressed in Jijoye and Clone-13
We previously described a mutant Burkitt's cell line, Clone-13 (29) , where HLA-DP and -DR are not expressed due to mutations in both alleles of the transcription factor CIITA (30) , and HLA-DQ is still expressed at a high level. In its parental cell line, Jijoye, with the presence of CIITA, all HLA molecules are expressed. It is now known that CIITA is a critical player in regulating multiple genes involved in antigen presentation (31) (32) (33) . However, evidence showed that other factors might exist that can also mediate antigen presentation (30, 34) . To identify other gene products germane to the immune response, we looked for additional genes that were differentially expressed between the Jijoye and Clone-13 cell lines using the technique of mRNA differential display (35) .
Sequence analysis of one of the differentially expressed species detected only in Clone-13 ( Fig. 1 ) turned out to completely match the BCL-6 cDNA sequence (from ϩ3344 bp to the polyA end). The BCL-6 gene, which was cloned from chromosomal translocations affecting band 3q27 (1), encodes for a 95-kD nuclear protein containing six C-terminal Kruppel-like zinc finger motifs (1-3) , and an N-terminal POZ domain homologous to members of zinc finger transcriptional factors (4) (5) (6) (7) (8) .
To verify the results of differential display (which was itself repeated three times with two independent RNA sample preparations), two primers specific for the human BCL-6 cDNA sequence (spanning base pairs ϩ427 to ϩ645, covering part of exon 3 and exon 4) were used in RT-PCR to detect BCL-6 mRNA in Jijoye and Clone-13. As shown in Figure 2A , BCL-6 mRNA was easily detected in the mutant cell line, Clone-13, whereas the BCL-6 PCR product in Jijoye was barely detectable. The same results were obtained with different RNA preparations and with another pair of PCR primers amplifying portion of the 3'-UTR (spanning base pairs ϩ1678 to ϩ1894; data not shown). Because the chromosomal breakpoints of the BCL-6 gene rearrangements cluster within a 4-kb region spanning the 5Ј flanking region, the first exon, and the first intron (1, 17) , leaving the coding domain intact, PCR products corresponding the coding region and 3'-UTR may better ascertain the presence of the BCL-6 transcripts. As controls, amplification products of HLA-DR␣ were only detected in Jijoye; products of GAPDH were nearly equivalent in the two cell lines, verifying the phenotype of the cells and controlling for RNA quality and PCR reactions.
Northern blot analysis was carried out using a 2.0-kb EcoR I fragment derived from the BCL-6 cDNA plasmid pMT2T-BCL-6 (10). A band with the expected size (3.8 kb) was readily detectable in Fig. 1 . Differential display of messenger RNA from Jijoye and Clone-13. Total RNA from each cell line was reverse transcribed and amplified by PCR in duplicate, using H-T11G as the anchor primer and H-AP6 (5'-AAGCTTGCACCAT-3') as the arbitrary primer. The radiolabeled PCR products were resolved on a 6% sequencing gel. The band indicated by the arrowhead was recovered from the gel. Upon sequence analysis, this particular mRNA was determined to be the BCL-6 mRNA. RT-PCR analysis of BCL-6 mRNA expression in Jijoye and Clone-13. Total RNAs were reverse transcribed with MMLV and random primers; a pair of primers specific for human BCL-6 cDNA was used in the following PCR reactions as described in Material and Methods. GAPDH and DR␣ were used as controls to evaluate the quality and amount of RNA samples used in RT-PCR. The data are representative of three independent analyses. (B) Northern blot analysis of BCL-6 mRNA in Jijoye, Clone-13 and Raji. Twenty micrograms of total RNA from each cell line was hybridized with a 2.0-kb EcoR I fragment derived from PMT2T-BCL6. The same blots were stripped and rehybridized with the GAPDH probe to evaluate the equivalency of RNA loading in each lane. cells (Fig. 3, lanes 1 and 3, respectively) , but not in Jijoye and Jurkat (Fig. 3 , lanes 2 and 4, respectively). These results clearly demonstrated that BCL-6 is differentially expressed in the two cell lines.
The BCL-6 Transcription Rate is Higher in Clone-13 than in Jijoye
The transcription rates of BCL-6 in these two cell lines were compared by nuclear run-on assay (Fig.  4A) . The intensity of the signals is quantified and shown as relative intensity (Fig. 4B) by subtracting the signal of empty vector pMT2T from plasmid pHeboMTBCL6 containing the full-length BCL-6 cDNA, and then compared to plasmid pSP64-␥-actin containing the ␥-actin cDNA. The results showed that the transcription rate in Clone-13 is approximately 5-fold of that in Jijoye (Fig. 4B) .
The BCL-6 Gene has no Gross Deletions in the Promoter (ϳ3 kb) and the First Intron in Jijoye/Clone-13
To determine whether structural alterations may have occurred in the BCL-6 gene that might explain the distinct BCL-6 expression phenotype of these cells, Southern blot analyses were performed using probes spanning the promoter, first exon, and first intron of the BCL-6 gene (Fig. 5A ). This is important in view of the propensity of the BCL-6 gene to undergo chromosomal translocations. Three bands with the expected size (3.7 kb, 1.3 kb, and 914 bp) were detected by probe 1 (Fig. 5B ), four bands (3.7 kb, 1.3 kb, 1.0 kb, and 676 bp) were detected by probe 2 (Fig.  5C ). These data suggest that there are no gross changes in the BCL-6 gene in these cell lines.
Multiple Mutations Cluster in the First Intron of the BCL-6 Gene in both Jijoye and Clone-13
To investigate whether point mutations in the BCL-6 gene may explain the higher transcription rate in Clone-13 than Jijoye, we amplified and cloned the hypermutable region of BCL-6 ( Fig. 6A ) from Clone-13 (Fig. 2B, lane 2) , and the intensity of the band is comparable to that in the BCL-6-positive cell line, Raji (Fig. 2B, lane 3) . However, only a trace amount of BCL-6 mRNA was detected in Jijoye (Fig.  2B, lane 1) . We next analyzed the BCL-6 protein levels in the two cell lines by Western blot analysis. BCL-6 proteins were detected in Raji and Clone-13 ) were harvested and washed with PBS. Cells were lysed with SDS-PAGE sample buffer. Cell lysates from each cell line were analyzed using the anti-Bcl-6 (N-3) and developed using an ECL kit. A 95-kb band corresponding to the BCL-6 protein was detected only in Raji and Clone-13 cell lines. both cell lines. By sequence analysis, we did find multiple, biallelic mutations in this region of the BCL-6 gene in both cell lines. As summarized in Table 1 , alterations include common and cellspecific single base pair substitutions, small deletions, and insertions.
We also scanned a large region of the BCL-6 gene promoter Ϫ300 bp to ϩ3188 and did not detect any mutations. These sequencing results suggest that mutations cluster within the hot-spot region analyzed above, consistent with the existing literature.
Point Mutations in the First Intron do not Influence Reporter Gene Expression In Vitro
We subsequently determined the biallelic distribution of some of the mutations. First, fragments of gene (Fig. 6A) . Multiple clones from each cell line were picked for sequence analysis using a sequencing primer starting from ϩ450 bp and primer B6AS1. The distribution of the mutations was separated into four types, corresponding to the four different alleles detected in the two cell lines (Table 2) . J4 and J6 are derived from the two alleles from Jijoye; C1 and C2 are from Clone-13.
To determine if these mutations alter the transcription rate of the downstream gene, we transfected the above four constructs into Jijoye and Clone-13 cells and measured their transcription activities. As shown in Figure 6B , the relative luciferase activities of the four constructs overlapped in both cell lines, indicating that the mutations in the first intron do not have a significant influence on gene expression in vitro.
Discussion
We have previously identified a pair of isogenic human B lymphoblastoid cell lines (Jijoye and Clone-13) that have distinct profiles of class II major histocompatibility complex (MHC) gene expression (29) . The Clone-13 cell line was derived from Jijoye, and expresses only HLA-DQ genes (␣ and ␤), whereas the Jijoye cell line expresses all three sets of class II genes (HLA-DR, DQ, and DP). Studies of these cell lines by cell fusion and transient transfection experiments have demonstrated that the lack of DR and DP gene expression in Clone-13 cells stems from a defect in a trans-acting factor influenced by the nature of a divergent class II cis-element termed the X2 box (36) . Fusion with a panel of class II MHC mutant B cell lines indicated the mutant gene in Clone-13 was identical to that found in another mutant cell line, RJ2.2.5 (37) .
The affected gene in RJ2.2.5, Clone-13, and other members of the complementation group was identified by complementation cloning experiments (38) . The polypeptide encoded by this factor, CIITA, functions as a master regulatory gene for antigen presentation, simultaneously activating several genes involved in immune recognition. Both alleles of the CIITA gene have been reported to harbor mutations in Clone-13 (30) . However, the disparate B6S1/B6AS1 (ϩ31 to ϩ1170 bp) were amplified from Jijoye and Clone-13 and then linked upstream of a ϳ3-kb BCL-6 promoter derived from plasmid pLA/B14.5 together with a downstream reporter class II MHC phenotypes of RJ2.2.5 (pan-class II negative) and Clone-13 (-DQ positive) suggest that there are other isotype-restricted phenomena occurring in Clone-13 that are distinct from CIITA (30, 34) .
One approach we used to identify factors involved in isotype-restricted MHC gene expression was to perform differential display on RNAs isolated from this and other isogenic cell pairs. This analysis would also be expected to potentially identify other genes regulated by CIITA (or other class II transactivators mutated in class II mutant B cells falling in other complementation groups).
One differentially expressed gene was found to be BCL-6 cDNA. The product of the BCL-6 gene, a Kruppel-like zinc finger protein (1-3), has been the focus of intensive investigations in recent years. Structural alterations of the 5' noncoding region of the BCL-6 gene leading to the expression of a normal protein under the control of heterologous promoters have been found in 40% of DLCL and 5-10% of follicular lymphomas (FL) (1, 15, 39) . The BCL-6 protein is predominantly expressed in germinal center B cells and related lymphomas, and also a small subpopulation of T cells (9) (10) (11) . Most interestingly, transgenic experiments implicate BCL-6 play important roles in germinal center formation, and in the IL-4 signaling pathway (22, 23) .
Our results clearly demonstrate that BCL-6 is differentially expressed in Jijoye and Clone-13. Previous studies have shown that BCL-6 can be regulated at transcriptional level as well as a posttranslational level through MAPK phosphorylation pathway (40, 41) . The Northern and Western analyses, together with the results of nuclear run-on assay, strongly suggest that BCL-6 expression is mainly controlled at the transcriptional level in Jijoye and Clone-13.
We did of course probe whether BCL-6 is regulated by CIITA or vice versa. This was done in two ways. First, we compared the expression profiles of CIITA, MHC class-II molecules, and BCL-6 in Jijoye/Clone-13 and another pair of B lymphoblastoid cell lines Raji/RJ2.2.5 (Table 3) . Raji expresses CIITA, all class-II genes, and BCL-6, whereas its derivative RJ2.2.5 is CIITA-negative and class IInegative but BCL-6 positive (data not shown). From Table 3 , no correlation is obvious between CIITA and BCL-6. Second, we directly asked whether ectopic expression of CIITA in CIITA-deficient HeLa cells could induce BCL-6 gene expression (and vice versa). Both experiments were negative (although control CIITA-dependent and BCL-6 repressed genes were induced or repressed as expected). Studies have shown that CIITA is regulated through the JAK1-STAT1 pathway (42), and we have found that STAT1 is also involved in induction of BCL-6 transcription by IFN-␥ in Jurkat cells (unpublished data). Thus it is more likely that BCL-6 and CIITA are both early response genes during B-cell development, but do not crossregulate each other.
Studies have shown that promoter substitutions caused by chromosomal translocations may cause deregulation of BCL-6 in a number of DLCL cases (17) . The majority of these breakpoints lie within the 5' portion of the first intron, and in a few cases the breakpoints are located immediately 5' to the promoter region (17) . However, in our case, gross deletions of the BCL-6 gene are not detected in these regions as shown by Southern blot analyses, and no promoter defects were found. Therefore, it is unlikely that the distinct expression of BCL-6 in the two cell lines is due to structural alterations of the gene.
Recent studies demonstrated that the BCL-6 gene accumulates large numbers of mutations in normal and malignant B cells with a pattern similar to that seen in Ig genes (21) . These mutations are independent of chromosomal rearrangements; and a stretch of 730 bp region ϳ100 bp downstream the first noncoding exon, which also overlaps the major cluster of chromosomal breakpoints, was determined to have the most frequent mutations (20) . It is In summary, we report a pair of B lymphoblastoid cell lines that exhibit distinct transcription of the BCL-6 gene. The multiple mutations in the first intron do not have effects on gene expression in vitro; promoter substitutions caused by chromosomal translocations are not detected in the two cell lines. Therefore, it is likely that the differences in transacting factor(s) explain the difference in BCL-6 transcription in these otherwise isogenic cell lines. Experiments comparing the occupancy of the promoter by trans-acting factors within the two cell lines are in progress to further map important regulatory mechanisms in BCL-6 gene expression. Preliminary data from these experiments suggest that the BCL-6 locus is occupied in both cell lines. This indicates that the differential expression of BCL-6 in the two cell lines is not due to differences in the general chromatin structure of the locus or to accessibility of the proximal promoter to binding by transcription factors. It is therefore likely that the difference in expression may be due to mutations in regulatory domains of these factors or to factors that are critical for transcription.
The existence of stable cell lines exhibiting distinct BCL-6 expression patterns should facilitate the elucidation of the regulatory mechanisms on the BCL-6 gene, just as they permitted the tremendous progress in research on class II MHC gene transcription over the past decade.
